Biblio
Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Differentiation of BCMA-specific induced pluripotent stem cells into CD8ab+ T cells targeting myeloma. Blood. 2023.
Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma. Transplant Cell Ther. 2021.
Immunologic Targets in AML. Blood Cancer Discov. 2023:OF1-OF3.
. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021;37(6):109992.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023.
Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(25):e2122379119.
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122-126.